Breaking News: MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics Insights | Financial Buzz

Breaking News: MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics Insights

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has completed work associated with a Research and Innovation Collaboration Agreement with Georgian College for a Data and Analytics Insights project. This four-month applied research project now complete, heightens MediPharm Labs abilities in diagnostic assessment of operations, analyzing quality management data, creating efficiencies and driving performance.

“We are pleased to have partnered with  a leading and innovative research institution to advance the data and analytics behind our cannabis extraction processes and methodology,” said Pat McCutcheon, CEO, MediPharm Labs. “This important work demonstrates our commitment to investing in building a foundation informed by data-driven decisions also supported by future predictive analytics.”

The goal of the collaboration was to create an operational dataset that provides insights and predictive analytics to help glean the highest purity, potency and efficiency from operations. The first phase of the project, completed in collaboration with faculty applied researchers and students from the Peter B. Moore Advanced Technology Centre,  established a relational database of original cannabinoid content and potency of cannabis flower inputs tracked through MediPharm Labs’ processes of Milling, Decarboxylation, Extraction, Winterization/Filtration, Solvent Removal, and Distillation through to end products.

“This has been an exciting opportunity for us to work with such an innovative company located right here in Barrie,” said Mira Ray, Director, Research, Innovation and Entrepreneurship at Georgian College. “MediPharm’s goal to be a data-driven company aligns with our Competitive Smart Manufacturing applied research and development program, which supports local businesses on their Industry 4.0 journey. The faculty and students from our Big Data Analytics program have helped MediPharm establish a strong foundation to collect, analyze and utilize their data for real-time decision-making, process improvements and overall productivity and quality gains.”

As part of the project, key performance indicators were established with standard calculation formulae and statistical methodology, enabling the R&D team and operational management to finetune processes with a deep understanding of impacts on quality and cost-effectiveness. The project delivered intuitive functional dashboards to monitor and provide diagnostic management tools to the operations team on a more timely basis. This Big Data project dovetailed with MediPharm Labs’ recent company-wide implementation of SAP, a Tier 1 Enterprise Resource Planning  system for data-driven decision making.

About Georgian College

Degrees, diplomas, certificates, apprenticeships and more – Georgian College offers more than 130 market-driven programs to accelerate your success. Georgian is a recognized leader in co-operative education and has one of the highest graduate employment rates among Ontario colleges. We’re known as a trailblazer in entrepreneurship and social innovation education. Georgian is home to 13,000 full-time students, including over 3,600 international students from 85 countries.

Research at Georgian College

The Research and Innovation department is the hub for research, development and innovation at Georgian, focusing on product design, prototyping, process optimization, testing and analysis, big data analytics, and digital solution development. Through industry and community-led activities, we foster a culture of research, scholarship and collegiality that connects students, employees and the community.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and completed commercialization of its Australian extraction facility which generated its first revenues in H1 2020.  MediPharm Labs Australia was established in 2017.

Sponsored Content Release. Click for Full Disclosure

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corp., investor relations, video production, filming editing, news reporting, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: